Loading organizations...
§ Public · Redwood City, CA, USA
Clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs) for solid tumor cancer treatment.
Founded in 2015 by Stanford University researcher Edgar Engleman and Michael Alonso, Bolt Biotherapeutics is a Redwood City, California-based clinical-stage oncology company developing immune-stimulating antibody conjugates. The organization utilizes its proprietary Boltbody platform to create therapies that link tumor-targeting antibodies with immune-stimulating agents, such as TLR7/8 agonists, rather than direct cell poisons. Under the leadership of Chief Executive Officer Willie Quinn, the firm is advancing its lead candidate, BDC-1001, through Phase 1 and Phase 2 clinical trials as a monotherapy for HER2-expressing solid tumors. Prior to entering the public markets, the enterprise secured over $177 million in venture capital funding from prominent institutional backers, including lead investors Sofinnova Investments and Pfizer Ventures. The biotechnology business subsequently raised an additional $230 million during its upsized initial public offering in 2021 to further support its growing immuno-oncology pipeline.
Bolt Biotherapeutics has raised $148.0M across 2 funding rounds.
Bolt Biotherapeutics has raised $148.0M in total across 2 funding rounds.
Bolt Biotherapeutics has raised $148.0M across 2 funding rounds. Most recently, it raised $94.0M Series C in June 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2020 | $94M Series C | Jason Pitts | Novo Ventures, Pivotal BioVenture Partners, Rivervest, Roche Venture Fund, SR ONE, RA Capital Management, Rock Springs Capital, Samsara BioCapital, Surveyor Capital, Vivo Capital | Announced |
| Feb 1, 2019 | $54M Series B | Pivotal BioVenture Partners | Novo Ventures, Rivervest, Roche Venture Fund, SR ONE, NAN Fung Life Sciences, Vivo Capital | Announced |
Bolt Biotherapeutics has raised $148.0M in total across 2 funding rounds.
Bolt Biotherapeutics's investors include Jason Pitts, Novo Ventures, Pivotal bioVenture Partners, RiverVest, Roche Venture Fund, SR One, RA Capital Management, Rock Springs Capital, Samsara BioCapital, Surveyor Capital, Vivo Capital, Nan Fung Life Sciences.
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies to treat cancer by harnessing the innate immune system.[1][2][3] It builds targeted therapies using its proprietary Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform, which combines tumor-targeting antibodies with immune-activating payloads to trigger myeloid cells and pattern recognition receptors, enabling the body to recognize and eradicate tumors.[1][3] The company serves patients with solid tumors, such as HER2-positive breast, colorectal, endometrial, gastroesophageal, head and neck, non-small cell lung, ovarian, and triple-negative breast cancers, addressing unmet needs in immuno-oncology where traditional treatments fall short.[2][3]
Key products include BDC-1001, an ISAC in clinical development for HER2-positive solid tumors, and BDC-3042, an agonist antibody targeting Dectin-2 to repolarize macrophages across various tumors.[2][3] Bolt has raised $340.5M in funding, including a $230M round, supporting its pipeline and collaborations with partners like Toray Industries, Genmab, Innovent Biologics, Bristol-Myers Squibb, and Roche.[2]
Bolt Biotherapeutics was founded in 2015 by Dr. Edgar G. Engleman, a Stanford University professor pioneering cancer immunotherapeutics and myeloid biology.[1] The idea emerged from Engleman's research on using foreign patterns to activate the innate immune system against cancer, expanding his academic work into a commercial platform.[1][3] Initially incorporated as Bolt Therapeutics, Inc., it rebranded to Bolt Biotherapeutics, Inc. in July 2015 and is headquartered in Redwood City, in the San Francisco Bay Area.[1][2]
Early traction came from assembling a management team with expertise in immuno-oncology drug discovery, development, and commercialization, alongside securing licenses from Stanford and partnerships that fueled its pipeline.[1][2] This foundation positioned Bolt as a biotech innovator bridging academia and industry.
Bolt rides the immuno-oncology wave, shifting from broad chemotherapies and checkpoint inhibitors to precise innate immune activation, amid rising demand for therapies tackling "cold" tumors resistant to PD-1/PD-L1 drugs.[1][3] Timing aligns with advances in myeloid cell research and antibody-drug conjugates (ADCs), where Bolt's ISAC twist adds immune stimulation for durable responses.[3]
Market forces favor it: surging biotech funding for next-gen cancer treatments, regulatory nods for myeloid-targeted assets, and partnerships signaling ecosystem validation.[2] Bolt influences the landscape by pioneering ISACs, inspiring combo therapies, and contributing to a collaborative model that accelerates oncology innovation beyond siloed development.[1][2][3]
Bolt's trajectory hinges on clinical readouts from BDC-1001 and BDC-3042, potentially unlocking blockbuster status in HER2+ and myeloid-reprogrammed tumors.[2] Upcoming milestones include trial expansions, combo studies with partners, and possible Phase 2/3 data by 2026, bolstered by its funding runway.[2]
Shaping trends—AI-driven target discovery, bispecifics, and innate immunity combos—could amplify Bolt's platform, evolving its role from pipeline developer to immuno-oncology leader. As innate immune therapies mature, Bolt stands poised to redefine cancer treatment, fulfilling its mission to eradicate tumors by empowering the body's defenses.[1][3]